Other Species / Isoforms
  SGTA (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K4-ac
____MDNkKRLAyAI
0 1
SGTA (human) ____MDNkKRLAyAI K4-ac
SGTA (mouse) ____MDNRKRLAYAI R4
SGTA (rat) ____MDNRKRLAYAI R4
Y9-p
DNkKRLAyAIIQFLH
0 5
SGTA (human) DNkKRLAyAIIQFLH Y9-p
SGTA (mouse) DNRKRLAYAIIQFLH Y9
SGTA (rat) DNRKRLAYAIIQFLH Y9
R76-m1
KEMPQDLrsPARtPP
0 1
SGTA (human) KEMPQDLrsPARtPP R76-m1
SGTA (mouse) QEMPQDPRAPDRtPP R77
SGTA (rat) KEMPQDPRGPDRtPP R76
S77-p
EMPQDLrsPARtPPs
Upstream
0 67
Treatment
  • nocodazole
SGTA (human) EMPQDLrsPARtPPs S77-p
SGTA (mouse) EMPQDPRAPDRtPPs A78
SGTA (rat) EMPQDPRGPDRtPPs G77
T81-p
DLrsPARtPPsEEDS
Upstream
0 97
Treatment
  • ischemia
SGTA (human) DLrsPARtPPsEEDS T81-p
SGTA (mouse) DPRAPDRtPPsEEDS T82-p
SGTA (rat) DPRGPDRtPPsEEDS T81-p
S84-p
sPARtPPsEEDSAEA
0 16
SGTA (human) sPARtPPsEEDSAEA S84-p
SGTA (mouse) APDRtPPsEEDSAEA S85-p
SGTA (rat) GPDRtPPsEEDSAEA S84-p
K95
SAEAERLKTEGNEQM
0 1
SGTA (human) SAEAERLKTEGNEQM K95
SGTA (mouse) SAEAERLKTEGNEQM K96
SGTA (rat) SAEAERLkTEGNEQM K95-ac
K95-ub
SAEAERLkTEGNEQM
0 3
SGTA (human) SAEAERLkTEGNEQM K95-ub
SGTA (mouse) SAEAERLKTEGNEQM K96
SGTA (rat) SAEAERLKTEGNEQM K95
K103-ub
TEGNEQMkVENFEAA
0 6
SGTA (human) TEGNEQMkVENFEAA K103-ub
SGTA (mouse) TEGNEQMkLENFEAA K104-ub
SGTA (rat) TEGNEQMKLENFEAA K103
K116-ub
AAVHFYGkAIELNPA
0 4
SGTA (human) AAVHFYGkAIELNPA K116-ub
SGTA (mouse) AAVHLYGKAIELNPA K117
SGTA (rat) AAVHLYGKAIELNPA K116
K137-ac
NRAAAYSkLGNyAGA
0 5
SGTA (human) NRAAAYSkLGNyAGA K137-ac
SGTA (mouse) NRAAAYSKLGNYVGA K138
SGTA (rat) NRAAAYSKLGNYVGA K137
K137-ub
NRAAAYSkLGNyAGA
0 36
SGTA (human) NRAAAYSkLGNyAGA K137-ub
SGTA (mouse) NRAAAYSkLGNYVGA K138-ub
SGTA (rat) NRAAAYSkLGNYVGA K137-ub
Y141-p
AYSkLGNyAGAVQDC
0 3
SGTA (human) AYSkLGNyAGAVQDC Y141-p
SGTA (mouse) AYSkLGNYVGAVQDC Y142
SGTA (rat) AYSkLGNYVGAVQDC Y141
Y158-p
AICIDPAyskAyGRM
0 9
SGTA (human) AICIDPAyskAyGRM Y158-p
SGTA (mouse) AIGIDPGySkAYGRM Y159-p
SGTA (rat) AIGIDPGYSkAYGRM Y158
S159-p
ICIDPAyskAyGRMG
0 1
SGTA (human) ICIDPAyskAyGRMG S159-p
SGTA (mouse) IGIDPGySkAYGRMG S160
SGTA (rat) IGIDPGYSkAYGRMG S159
K160-ac
CIDPAyskAyGRMGL
0 2
SGTA (human) CIDPAyskAyGRMGL K160-ac
SGTA (mouse) GIDPGySKAYGRMGL K161
SGTA (rat) GIDPGYSkAYGRMGL K160-ac
K160-ub
CIDPAyskAyGRMGL
Upstream
0 114
Treatment
  • vorinostat
SGTA (human) CIDPAyskAyGRMGL K160-ub
SGTA (mouse) GIDPGySkAYGRMGL K161-ub
SGTA (rat) GIDPGYSkAYGRMGL K160-ub
Y162-p
DPAyskAyGRMGLAL
0 2
SGTA (human) DPAyskAyGRMGLAL Y162-p
SGTA (mouse) DPGySkAYGRMGLAL Y163
SGTA (rat) DPGYSkAYGRMGLAL Y162
S171-p
RMGLALSsLNkHVEA
0 1
SGTA (human) RMGLALSsLNkHVEA S171-p
SGTA (mouse) RMGLALSSLNkHAEA S172
SGTA (rat) RMGLALSSLNKHAEA S171
K174-ub
LALSsLNkHVEAVAY
0 3
SGTA (human) LALSsLNkHVEAVAY K174-ub
SGTA (mouse) LALSSLNkHAEAVAY K175-ub
SGTA (rat) LALSSLNKHAEAVAY K174
K183-ub
VEAVAYYkkALELDP
0 2
SGTA (human) VEAVAYYkkALELDP K183-ub
SGTA (mouse) AEAVAYYKkALELDP K184
SGTA (rat) AEAVAYYKKALELDP K183
K184-ub
EAVAYYkkALELDPD
0 7
SGTA (human) EAVAYYkkALELDPD K184-ub
SGTA (mouse) EAVAYYKkALELDPD K185-ub
SGTA (rat) EAVAYYKKALELDPD K184
K196-ub
DPDNETYkSNLkIAE
0 7
SGTA (human) DPDNETYkSNLkIAE K196-ub
SGTA (mouse) DPDNDTYkSNLkIAE K197-ub
SGTA (rat) DPDNDTYKSNLkIAE K196
K200-ub
ETYkSNLkIAELkLR
0 74
SGTA (human) ETYkSNLkIAELkLR K200-ub
SGTA (mouse) DTYkSNLkIAELkLR K201-ub
SGTA (rat) DTYKSNLkIAELKLR K200-ub
K205-ub
NLkIAELkLREAPSP
0 12
SGTA (human) NLkIAELkLREAPSP K205-ub
SGTA (mouse) NLkIAELkLREAPSP K206-ub
SGTA (rat) NLkIAELKLREAPSP K205
S297-p
ELIEQLRsQIRsRtP
0 15
SGTA (human) ELIEQLRsQIRsRtP S297-p
SGTA (mouse) EFVEQIRsQVVRsRt S298-p
SGTA (rat) EFVEQIRSQVVRsRt S297
S301-p
QLRsQIRsRtPsAsN
Upstream
0 112
Treatment
  • erlotinib
  • selumetinib
  • vemurafenib
SGTA (human) QLRsQIRsRtPsAsN S301-p
SGTA (mouse) IRsQVVRsRtPsAsH S303-p
SGTA (rat) IRSQVVRsRtPsASH S302-p
T303-p
RsQIRsRtPsAsNDD
Upstream
0 125
Treatment
  • EGF
  • imatinib
  • SB202190
  • selumetinib
  • U0126
  • vemurafenib
SGTA (human) RsQIRsRtPsAsNDD T303-p
SGTA (mouse) sQVVRsRtPsAsHEE T305-p
SGTA (rat) SQVVRsRtPsASHEE T304-p
S305-p
QIRsRtPsAsNDDQQ
Upstream
Downstream
1 621
SGTA (human)
S305-p
Effects on Modified Protein
  • molecular association, regulation
Putative in vivo kinases:
  • Akt2 (mouse)
Treatment
  • angiotensin_2
  • dasatinib
  • EGF
  • erlotinib
  • gefitinib
  • imatinib
  • PDGF
  • quinalizarin
  • SB202190
  • selumetinib
  • Su11274
  • U0126
  • vemurafenib
SGTA (human) QIRsRtPsAsNDDQQ S305-p
SGTA (mouse) VVRsRtPsAsHEEQQ S307-p
SGTA (rat) VVRsRtPsASHEEQQ S306-p
S307-p
RsRtPsAsNDDQQE_
0 143
SGTA (human) RsRtPsAsNDDQQE_ S307-p
SGTA (mouse) RsRtPsAsHEEQQE_ S309-p
SGTA (rat) RsRtPsASHEEQQE_ S308